Health‐related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan‐Canadian Oncology Drug Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Health‐related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan‐Canadian Oncology Drug Review

Published:2019-09-23 Issue:1 Volume:126 Page:148-155
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Raymakers Adam J. N.¹²³^ORCID,Regier Dean A.¹²⁴,Peacock Stuart J.¹²³

Affiliation:

1. Canadian Centre for Applied Research in Cancer Control Vancouver British Columbia Canada

2. Cancer Control Research, BC Cancer Vancouver British Columbia Canada

3. Faculty of Health Sciences Simon Fraser University Burnaby British Columbia Canada

4. School of Population and Public Health University of British Columbia Vancouver British Columbia Canada

Funder

Genome Canada

Canadian Institutes of Health Research

Breast Cancer Research Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32455

Reference20 articles.

1. Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

2. How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

3. Systematic overview of cost–effectiveness thresholds in ten countries across four continents

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses;PharmacoEconomics - Open;2024-08-05

2. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS;Journal of Cancer Research and Clinical Oncology;2024-03-04

3. A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries;Applied Health Economics and Health Policy;2024-01-12

4. Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?;Clinical Drug Investigation;2023-07-28

5. Author Reply;Value in Health;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3